The clinical course of sarcoidosis: Presentation, diagnosis, and treatment in a large white and black cohort in the United States

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 29, Issue 2, 2012, Pages 119-127

  Judson, Marc A ^a,b   Boan, A D ^c   Lackland, D T ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Corticosteroids; Diagnosis; Phenotype; Sarcoidosis; Treatment

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AFRICAN AMERICAN; ARTICLE; BIOPSY; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; LUNG FUNCTION; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RACE DIFFERENCE; SARCOIDOSIS; SEX DIFFERENCE; THORAX RADIOGRAPHY; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MIDDLE AGED; PREVALENCE; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SOUTH CAROLINA; TIME FACTORS;

EID: 84872300306     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pietinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 158-66. (Pubitemid 30411832)
2. Behbehani N, Jayakrishnan B, Khadadah M, et al. Long term prognosis of sarcoidosis in Arabs and Asians: predictors of good outcome. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 209-14. (Pubitemid 47596316)
3. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 204-11. (Pubitemid 37351542)
4. Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999; 5: 293-8.
5. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med 2008; 29: 415-427, viii. (Pubitemid 351784487)
6. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vase Diffuse Lung Dis 1999; 16: 149-73.
7. Judson MA. A proposed solution to the clinical assessment of sarcoidosis: the sarcoidosis three-dimensional assessment instrument (STAI). Med Hypotheses 2007; 68: 1080-7. (Pubitemid 46274036)
8. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 1999; 16: 75-86. (Pubitemid 29164274)
9. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115: 1158-65. (Pubitemid 29193691)
10. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104: 717-23.
11. McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339: 1-4.
12. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66. (Pubitemid 30157757)
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87. (Pubitemid 29036522)
14. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-89. (Pubitemid 33152325)
15. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Qjm 2006; 99: 307-15.
16. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-31. (Pubitemid 27132936)
17. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78: 65-111. (Pubitemid 29153026)
18. Judson MA. Cardiac sarcoidosis: there is no instant replay. Chest 2005; 128: 3-6. (Pubitemid 40994442)
19. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157: 9-21.
20. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88:1006-10. (Pubitemid 33042612)
21. Huang CT, Heurich AE, Sutton AL, et al. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur J Respir Dis 1981; 62: 231-8. (Pubitemid 11062099)
22. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003; 123: 406-12. (Pubitemid 36269422)
23. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. Jama 2002; 287: 1301-7. (Pubitemid 34250485)
24. Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982; 29: 27-32. (Pubitemid 12149959)